Consolidated Statements of Changes in Equity (USD $)	Total	Common Stock	Treasury Stock	Series A Preferred Stock	Additional Paid in Capital	Statutory Reserve	Retained Earnings	Accumulated other Comprehensive Income	Total Shareholder's Equity	Noncontrolling Interest
Beginning Balance at Jun. 30, 2011	$ 81,279,562	$ 29,396	$ (111,587)		$ 30,065,452	$ 5,409,764	$ 39,374,018	$ 6,077,299	$ 80,844,342	$ 435,220
Beginning Balance, Shares at Jun. 30, 2011		29,312,491
Net Income	6,241,918						6,358,690		6,358,690	(116,772)
Other comprehensive income:
Foreign currency translation adjustment	2,065,066							2,023,227	2,023,227	41,839
Comprehensive income	8,306,984								8,381,917	(74,933)
Common shares issued	39,500	50			39,450				39,500
Common shares issued, Shares		50,000
Treasury stock	(24,338)		(24,338)						(24,338)
Treasury stock, Shares		(29,700)
Contribution from noncontrolling interest for Jiangchuan Pharmaceutical Co., Ltd.	252,352									252,352
Purchase of subsidiary shares from noncontroll interest	(334,613)									(334,613)
Statutory reserve						710,379	(710,379)
Ending Balance at Jun. 30, 2012	89,519,447	29,446	(135,925)		30,104,902	6,120,143	45,022,329	8,100,526	89,241,421	278,026
Ending Balance, Shares at Jun. 30, 2012		29,332,791
Net Income	6,615,173						6,672,151		6,672,151	(56,978)
Other comprehensive income:
Foreign currency translation adjustment	2,083,061							2,077,832	2,077,832	5,229
Comprehensive income	8,698,234								8,749,983	(51,749)
Common shares issued	30,000	50			29,950				30,000
Common shares issued, Shares		50,000
Treasury stock
Treasury stock, Shares
Statutory reserve						727,172	(727,172)
Ending Balance at Jun. 30, 2013	$ 98,247,681	$ 29,496	$ (135,925)		$ 30,134,852	$ 6,847,315	$ 50,967,308	$ 10,178,358	$ 98,021,404	$ 226,277
Ending Balance, Shares at Jun. 30, 2013		29,382,791